BRIEF-Morphosys, Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis
Sept 29 Morphosys Ag
* Says Morphosys and Galapagos start first-in-patient dosing of IL-17C antibody MOR106 in atopic dermatitis
* Says favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in study to date Source text for Eikon: Further company coverage:
UPDATE 3-American Airlines apologizes for onboard clash over stroller
NEW YORK, April 22 American Airlines on Saturday apologized to a female passenger and suspended an employee after a video showing an onboard clash over a baby stroller went viral, in the latest embarrassment for a U.S. carrier over how it treated a customer.
EU mulls legislation in the fight against online hate speech
BRUSSELS, April 22 The European Union is considering legislative measures to harmonise how online platforms like Facebook, Twitter and Google take down hate speech and incitement to violence, a draft document seen by Reuters shows.